🧾 What This Document Is

This is a preliminary proxy statement (PRE 14A) for Omnicell's 2026 Annual Meeting. Think of it as a detailed "voting guide" and information packet sent to shareholders before the meeting. It explains what the company wants shareholders to vote on and provides background info so they can make informed decisions. Since it's preliminary, some details might change slightly before the final version is sent.

🏢 What The Company Does

In simple terms: Omnicell provides technology solutions for medication management in healthcare settings (like hospitals and pharmacies). Their automated systems help pharmacies dispense drugs accurately, manage inventory, and improve patient safety – think robotic dispensing cabinets and software to track medications.

📅 Meeting & Voting Basics

When: May 19, 2026, at 4:30 p.m. Eastern Time (virtual only).
Record Date: March 27, 2026. Only shareholders owning stock on this date can vote.
Shares Outstanding: 45,477,299 shares on the record date.
Quorum Needed: Holders of at least 22,738,650 shares must be present (virtually or by proxy).
How to Vote: By mail, phone (1-800-652-8683), Internet (investorvote.com/OMCL), or virtually during the meeting. Details on registering for the virtual meeting are provided.

🔥 What Shareholders Are Voting On

Omnicell needs shareholders to vote on 5 key proposals:

Proposal 1: Elect Directors
- Who: Vote on 3 Class I nominees for 3-year terms ending 2029:
  - Joanne B. Bauer (70, Lead Independent Director since 2014, healthcare industry experience)
  - Robin G. Seim (66, Director since 2019, former Omnicell CFO & President, deep company knowledge)
  - Eileen J. Voynick (71, Director since 2024, software/healthcare executive experience)
- Recommendation: The Board recommends a "FOR" vote for all three.
- Note: Directors are elected by plurality (most "For" votes), but a majority-vote resignation policy applies (if more "Withheld" than "For", director must offer resignation).
Proposal 2: Advisory Vote on Executive Compensation ("Say-on-Pay")
- What: A non-binding vote to approve how the company pays its top executives.
- Recommendation: The Board recommends a "FOR" vote.
- Why it matters: Gives shareholders a voice on pay practices, though it doesn't force changes.
Proposal 3: Approve Amendment to 2009 Equity Incentive Plan
- What: Increase the number of shares available for grants (stock options, RSUs, etc.) by 1,600,000 shares.
- Recommendation: The Board recommends a "FOR" vote.
- Why it matters: More shares mean the company can continue granting equity to attract/retain employees, but it dilutes existing shareholders.
Proposal 4: Approve Certificate of Incorporation Amendment (Officer Exculpation)
- What: Add language protecting certain officers (not directors) from personal liability for some breaches of duty, as allowed by recent Delaware law changes. Also includes minor, non-substantive updates.
- Vote Needed: Requires 66 2/3% approval of outstanding voting power.
- Recommendation: The Board recommends a "FOR" vote.
- Why it matters: Reduces personal financial risk for officers acting in good faith, potentially making leadership roles more attractive.
Proposal 5: Ratify Deloitte & Touche LLP as Auditors for 2026
- What: Shareholders formally approve the selection of Deloitte as the independent accounting firm.
- Recommendation: The Board recommends a "FOR" vote.
- Why it matters: Standard corporate governance practice. Brokers can vote this proposal even without shareholder instruction ("routine" matter).

👥 Board & Governance Highlights

Board Structure: 9 directors (3 classes). 89% are independent. Combines CEO (Randall Lipps) and Chairman roles, supported by a strong Lead Independent Director (Joanne Bauer).
Key Committees:
- Audit (Seim Chair): Oversees finances, audits, risk (incl. cybersecurity). Met 13 times in 2025.
- Compensation (Garrett Chair): Sets exec pay, oversees equity plans. Met 4 times in 2025. Uses consultant Exequity LLP.
- Corporate Governance (Scott Chair): Handles director nominations, governance, ESG. Met 4 times in 2025.
- M&A (Bousa Chair): Reviews M&A deals up to $100M. Met 2 times in 2025.
Stock Ownership: Guidelines require significant skin in the game: Directors (5x retainer), CEO (6x salary), other NEOs (3x salary). All meet or are on track.
Risk Oversight: Board & committees oversee strategic, financial, operational, cybersecurity, and compensation risks. Audit Committee gets regular cybersecurity updates.
Attendance: All directors attended 75%+ of 2025 meetings. All 9 attended the 2025 Annual Meeting.
Policies: Strong code of ethics, insider trading/hedging policies, related party transaction review.

💰 Executive Compensation Snapshot

Process: Set by independent Compensation Committee, advised by Exequity LLP. Focuses on pay-for-performance and market competitiveness.
Elements: Base salary, annual bonus (based on financial/operational goals), long-term equity (performance-based RSUs and stock options).
2025 Highlights (Due to Exec Changes):
- Randall Lipps (CEO/Pres): Total Comp $6,558,705 (Base $680k, Bonus $765k, Equity ~$5.1M).
- Corey Manley (CLO/Sec): Total Comp $3,010,652 (Base $420k, Bonus $353k, Equity ~$2.2M). Promoted to CLO June 2025.
- Nhat H. Ngo (CRO): Total Comp $1,899,506 (Base $295k, Bonus $180k, Equity ~$1.4M). Left Dec 2025.
- Brett J. Picotte (CFO): Total Comp $1,320,000 (Base $400k, Bonus $200k, Equity ~$720k). Hired May 2025.
- Suresh K. Lakshmanan (CTO): Total Comp $1,487,159 (Base $375k, Bonus $180k, Equity ~$932k). Left Dec 2025.
CEO Pay Ratio: ~109:1 (CEO Pay / Median Employee Pay).

🔮 What's Next & Why This Meeting Matters

This meeting is crucial for Omnicell's governance and strategic direction. Shareholder votes will decide:

Future Leadership: Who sits on the Board to oversee the company.
Talent Strategy: Whether the company gets enough equity to attract/retain key talent (Proposal 3).
Officer Protections: Whether officers get added liability protection (Proposal 4).
Approval of Oversight: Endorsing the Board's handling of exec pay and the choice of auditor.

The company emphasizes the need for strong equity compensation to compete for talent in a challenging market. The officer exculpation amendment aligns with modern Delaware corporate practices.

⚖️ Big Picture

👍 Strengths:
- Experienced Board with strong independence (89%) and relevant healthcare/tech expertise.
- Clear governance structure with robust committee oversight (especially Audit on cybersecurity).
- Performance-based executive compensation design.
- Strong stock ownership requirements align leadership with shareholders.
⚠️ Risks:
- Significant executive and board turnover/refreshment in recent years (e.g., new CFO, CLO, CTO, directors).
- Ongoing business transformation and operational challenges implied by executive changes.
- Dilution impact from the proposed 1.6M share increase in the equity plan.
- The officer exculpation proposal reduces a potential deterrent for misconduct (though focused on good-faith actions).

🧠 The Analogy

Imagine Omnicell is a large ship navigating tricky waters (healthcare tech market). This meeting is the crew (shareholders) checking the map (proxy), confirming the officers (Board, execs) are the right ones, voting on whether to give them more tools (equity plan), and deciding if they need slightly less personal liability for tough calls (exculpation). Everyone needs to agree on the course to reach the destination safely and successfully.

📇 Key Contacts & People

Corporate Secretary: Corey J. Manley (signs the Notice)
Investor Contact (for Proxy Materials): Available at https://ir.omnicell.com/financials/annual-reports-and-proxy-statements
Transfer Agent (Computershare): [email protected] (for beneficial owners needing a legal proxy to vote virtually)

🧩 Final Takeaway

Omnicell's 2026 Annual Meeting asks shareholders to endorse its Board nominees, executive pay, and key governance changes (more equity for employees, liability protection for officers), while ratifying its auditor. Shareholder approval of Proposals 3 & 4 is critical for the company's ability to motivate talent and align with modern corporate legal standards. The meeting reflects a company in transition, refreshing leadership and seeking tools to navigate the competitive healthcare tech landscape.

OMNICELL, INC. — PRE 14A Filing